Carolyn Hoppe

Summary

Affiliation: Childrens Hospital & Research Center Oakland
Location: Oakland, USA
URL: www.rbclab.com
Summary:
Dr. Hoppe is an associate hematologist-oncologist and clinical scientist at Childrens Hospital & Research Center Oakland. She has been an integral team member of the Northern California Comprehensive Sickle Cell Program for the past ten years. As the medical director of the CHRCO Hemoglobinopathy Reference Laboratory and the California State Newborn Screening for Hemoglobinopathies Follow-up Program, she has has expanded the services provided by this program to include novel methods for molecular diagnostic testing for sickling and thalassemic disorders. Together with Dr. Frans Kuypers, she codirects the Red Blood Cell Laboratory to provide a resource for clinical diagnostics and translational research. She has more recently extended her research focus on genetic modifiers of stroke in sickle cell disease to clinical investigations of statins in patients with sickle cell disease.
Grants:
HLA Type and Stroke in Children with Sickle Cell Anemia.
1999-2001. American Society of Hematology, Fellow Scholar Award.

Genetic Predictors of Stroke in Children with Sickle Cell Anemia. 2000-2005. Doris Duke Charitable Foundation, Clinical Scientist Development Award.

Arginine Therapy for Acute Chest Syndrome in Sickle Cell Disease. 2001-2005. Co-investigator, FD-R-1978-01 FDA Orphan Products Development(Styles, PI).

Feasibility Study to Investigate the Creation and Use of a Referral Laboratory to Assist State Newborn Hemoglobinopathy Screening Programs. 2003-2005.
HRSA/National Newborn Screening and Genetics Resource Center.

Genetic Determinants of Stroke Risk in Adults with Sickle Cell Anemia. 2005-2008. NHLBI Research Training Supplement to the Comprehensive Sickle Cell Centers, PA-01-079.

NHLBI CSCC Collaborative Genotype-Phenotype Database and Sample Repository. 2006-2008. U54 HL70583 (Hoppe, PI).

Analysis of Rh Blood Group Genes to Improve Transfusion Therapy in Sickle Cell Disease. 2007-2010. NHLBI 1R01 HL091030 (Reid, PI).

Indo-US collaborative project on Maternal and Child Health and Human Development Research: Pilot study of Newborn Screening for Haemoglobinopathies in South Gujarat, India.
2008-2010. 1R03 HD57740-01 (Krishnamurti, PI).

Phase I/II Trial of Simvastatin (Zocor)in Sickle Cell Disease. 2007-2011. FDA/OPD, 1R01FD-03080-01-A1 (Hoppe, PI).

An Open Label, Dose Ranging Study of Prasugrel in Pediatric Patients with Sickle Cell Disease. 2011-2013. Eli Lilly and Company (Styles, PI).

Publications

  1. ncbi Gene interactions and stroke risk in children with sickle cell anemia
    Carolyn Hoppe
    Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Blood 103:2391-6. 2004
  2. ncbi Evidence for HLA-related susceptibility for stroke in children with sickle cell disease
    L A Styles
    Department of Hematology Oncology, Children s Hospital Oakland, Oakland, CA 94609, USA
    Blood 95:3562-7. 2000
  3. pmc A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction
    Carolyn Hoppe
    Department of Haematology Oncology, Children s Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA
    Br J Haematol 153:655-63. 2011
  4. doi Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease
    Elsie Gyang
    Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA
    Am J Hematol 86:104-6. 2011
  5. pmc A novel RHCE*ce 48C, 733G allele with Nucleotide 941C in Exon 7 encodes an altered red blood cell e antigen
    Kim Hue-Roye
    Laboratory of Immunochemistry, New York Blood Center, New York, New York 10065, USA
    Transfusion 51:32-5. 2011
  6. ncbi Newborn screening for non-sickling hemoglobinopathies
    CAROLYN C HOPPE
    Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    Hematology Am Soc Hematol Educ Program . 2009
  7. doi Definitions of the phenotypic manifestations of sickle cell disease
    Samir K Ballas
    Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
    Am J Hematol 85:6-13. 2010
  8. ncbi HLA type and risk of alloimmunization in sickle cell disease
    Carolyn Hoppe
    Am J Hematol 84:462-4. 2009
  9. doi Newborn screening for hemoglobinopathies in California
    Jennifer Michlitsch
    Children s Hospital and Research Center Oakland, Oakland, California 94609, USA
    Pediatr Blood Cancer 52:486-90. 2009
  10. pmc Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
    Chutima Kumkhaek
    Molecular and Clinical Hematology Branch, NIDDK, NIH, Bethesda, MD, USA
    Br J Haematol 141:254-9. 2008

Research Grants

Collaborators

Detail Information

Publications23

  1. ncbi Gene interactions and stroke risk in children with sickle cell anemia
    Carolyn Hoppe
    Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Blood 103:2391-6. 2004
    ..If confirmed, these results provide a basis for population screening and targeted intervention to prevent stroke in SCA...
  2. ncbi Evidence for HLA-related susceptibility for stroke in children with sickle cell disease
    L A Styles
    Department of Hematology Oncology, Children s Hospital Oakland, Oakland, CA 94609, USA
    Blood 95:3562-7. 2000
    ..Specific HLA alleles may influence the risk of stroke in children with SCA. HLA typing may prove useful in identifying SCA patients at higher risk for stroke...
  3. pmc A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction
    Carolyn Hoppe
    Department of Haematology Oncology, Children s Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA
    Br J Haematol 153:655-63. 2011
    ..Simvastatin was well-tolerated and safe. Our preliminary findings showing a dose-related effect of simvastatin on levels of NOx, CRP and IL-6 suggest a potential therapeutic role for simvastatin in SCD...
  4. doi Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease
    Elsie Gyang
    Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA
    Am J Hematol 86:104-6. 2011
    ..We conclude that adherence to CTX does not necessarily prevent SI or halt cerebral vasculopathy progression, especially in those with a history of overt stroke...
  5. pmc A novel RHCE*ce 48C, 733G allele with Nucleotide 941C in Exon 7 encodes an altered red blood cell e antigen
    Kim Hue-Roye
    Laboratory of Immunochemistry, New York Blood Center, New York, New York 10065, USA
    Transfusion 51:32-5. 2011
    ..We also screened blood samples from African Americans to determine the frequency of the novel allele...
  6. ncbi Newborn screening for non-sickling hemoglobinopathies
    CAROLYN C HOPPE
    Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    Hematology Am Soc Hematol Educ Program . 2009
    ..This review will consider the increasing prevalence of once uncommon hemoglobinopathies in the US, highlighting the rationale for expanding newborn screening beyond sickle cell disorders...
  7. doi Definitions of the phenotypic manifestations of sickle cell disease
    Samir K Ballas
    Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
    Am J Hematol 85:6-13. 2010
    ....
  8. ncbi HLA type and risk of alloimmunization in sickle cell disease
    Carolyn Hoppe
    Am J Hematol 84:462-4. 2009
  9. doi Newborn screening for hemoglobinopathies in California
    Jennifer Michlitsch
    Children s Hospital and Research Center Oakland, Oakland, California 94609, USA
    Pediatr Blood Cancer 52:486-90. 2009
    ..In 1999, newborn screening for Hb H disorders was incorporated in the statewide hemoglobinopathy screening program...
  10. pmc Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
    Chutima Kumkhaek
    Molecular and Clinical Hematology Branch, NIDDK, NIH, Bethesda, MD, USA
    Br J Haematol 141:254-9. 2008
    ..These data suggest that variation within SAR1A regulatory elements might contribute to inter-individual differences in regulation of HbF expression and patient responses to HC in SCD...
  11. ncbi Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia
    Carolyn Hoppe
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    Stroke 38:2241-6. 2007
    ..The aim of this replication study was to confirm our previous findings of associations between the TNF(-308) G/A, IL4R 503 S/P, and ADRB2 27 Q/E polymorphisms and large vessel stroke risk...
  12. ncbi Distinct HLA associations by stroke subtype in children with sickle cell anemia
    Carolyn Hoppe
    Department of Hematology Oncology, Children s Hospital Oakland, CA 94609, USA
    Blood 101:2865-9. 2003
    ..If these results are confirmed in a larger study, HLA type may serve as a useful marker for the early identification of SCA patients at high risk for stroke...
  13. ncbi Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease
    C Hoppe
    Department of Hematology Oncology, Children s Hospital Oakland, California 94609, USA
    J Pediatr Hematol Oncol 22:330-4. 2000
    ..No unexpected toxicity occurred, and growth and development were unaffected. This pilot study suggests that hydroxyurea is safe and effective in young children with sickle cell disease...
  14. ncbi Bioinformatics: computers or clinicians for complex disease risk assessment?
    Carolyn Hoppe
    Eur J Hum Genet 13:893-4. 2005
  15. ncbi Defining stroke risk in children with sickle cell anaemia
    Carolyn Hoppe
    Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, Oakland, CA 94609, USA
    Br J Haematol 128:751-66. 2005
    ....
  16. ncbi A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia
    C Hoppe
    Department of Hematology Oncology, Children s Hospital Oakland, Oakland, CA 94609, USA
    Br J Haematol 114:718-20. 2001
    ..These preliminary results on a small group of patients suggest that a multilocus genotyping assay may be valuable in identifying genes that increase the risk of stroke in SCA...
  17. ncbi Application of flow cytometry-based genotyping for rapid detection of hemoglobin variants
    S Aslanian
    Hemoglobinopathy Reference Laboratory, Children s Hospital Oakland Research Institute, Oakland, CA 94609, USA
    Int J Lab Hematol 29:284-91. 2007
    ..This pilot study demonstrates the potential application of the Luminex LabMAP genotyping platform to newborn screening for definitive hemoglobinopathy testing...
  18. doi Inflammatory mediators of endothelial injury in sickle cell disease
    CAROLYN C HOPPE
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA Electronic address
    Hematol Oncol Clin North Am 28:265-86. 2014
    ..Mediators of inflammation, such as cellular adhesion molecules, cytokines, leukotrienes, and nuclear factor κB signaling factors, represent potential therapeutic targets in sickle cell disease. ..
  19. doi Prenatal and newborn screening for hemoglobinopathies
    C C Hoppe
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, CA 94609, USA
    Int J Lab Hematol 35:297-305. 2013
    ..This review summarizes the current approaches and methods used for carrier detection, prenatal diagnosis, and newborn screening...
  20. doi Novel therapies targeting the endothelium in sickle cell disease
    CAROLYN C HOPPE
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, California 94609, USA
    Hemoglobin 35:530-46. 2011
    ..This review will discuss novel drugs, specifically targeted at the endothelium, that are currently under investigation in sickle cell disease...
  21. doi Newborn screening for hemoglobin disorders
    CAROLYN C HOPPE
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, California 94609, USA
    Hemoglobin 35:556-64. 2011
    ....
  22. ncbi Pediatric thrombosis
    Carolyn Hoppe
    Children s Hospital and Research Center at Oakland, 747 52nd Street, Oakland, CA 94609, USA
    Pediatr Clin North Am 49:1257-83. 2002
    ..Prospective and multicenter studies are still needed to clarify the contribution of specific prothrombotic disorders to childhood TE so that evidence-based treatment recommendations can be made...
  23. ncbi Prevalence of HFE mutations in California newborns
    Carolyn Hoppe
    Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, Oakland, California 94609, USA
    Pediatr Hematol Oncol 23:507-16. 2006
    ..4/1000. As additional genetic and environmental risk factors for HHC are identified, neonatal screening may become an acceptable strategy to follow susceptible individuals and prevent clinical disease...

Research Grants2

  1. PHASE I/II STUDY OF SIMVASTATIN (ZOCOR) THERAPY IN SICKLE CELL DISEASE
    Carolyn Hoppe; Fiscal Year: 2007
    ..To determine the effect of oral simvastatin (Zocor) on vascular physiology in SCD, as measured by peripheral blood markers of endothelial injury. 2. To assess the safety and tolerability of oral simvastatin in patients with SCD. ..